Clinical Trial Update: Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) [Phase 2]

View source ↗

Summary

Phase 2 trial update on pemigatinib in solid tumors with FGFR mutations or translocations; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors with Fgfr Mutations
• Solid Tumors with Fgfr Translocations

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Advanced or Metastatic Solid Tumors, FGFR Mutations | Phase 2 | Status: TERMINATED | Results posted: 2022-04-21